CN103386115B - The application of Thymopentin in preparation treatment mastitis medicine - Google Patents
The application of Thymopentin in preparation treatment mastitis medicine Download PDFInfo
- Publication number
- CN103386115B CN103386115B CN201210146059.2A CN201210146059A CN103386115B CN 103386115 B CN103386115 B CN 103386115B CN 201210146059 A CN201210146059 A CN 201210146059A CN 103386115 B CN103386115 B CN 103386115B
- Authority
- CN
- China
- Prior art keywords
- thymopentin
- medicine
- mastitis
- milk
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to drug world, the particularly application of Thymopentin in preparation treatment mastitis medicine.Latent mammitis test of pesticide effectiveness result shows, the infection of Thymopentin treatment group breast district quantity has the trend of minimizing after the treatment, is obvious especially with high dose group (4mg).The clinic mastitis test of pesticide effectiveness shows, through for three days on end after lymphonodi mammarici injection Thymopentin (TP-5), the milk SCC of TP-5 bis-dosage groups (10mg, 20mg) all has downward trend, and the swelling of visual inspection cow breast is clearly better.Therefore the medicine that high dose Thymopentin (more than 10mg) is obtained is to the Be very effective of milch cow clinic mastitis.As can be seen here, the medicine that Thymopentin is obtained has remarkable result to latent mammitis and/or clinic mastitis.
Description
Technical field
The present invention relates to drug world, the particularly application of Thymopentin in preparation treatment mastitis medicine.
Background technology
Mastitis is mainly due to a kind of inflammation that bacteriological infection mammary gland tissue causes.Papillary duct is the main path that antibacterial invades that mammary gland causes infection, and under health status, papillary duct epithelial cells keratin etc. have the material of antibacterial action, is the first line of defence that antibacterial intrusion mammary gland runs into.When papillary duct because the reason such as to milk is damaged, the function of epithelial cells antibiotic substance wrecks, and antibacterial easily enters mammary gland.When antibacterial breaks through the physical barriers of nipple, the second defence line run into after invading mammary gland is body fluid in mammary gland and cellularity defending factors.Humoral factor comprises immunoglobulin, complement, lactoferrin, lysozyme and peroxide enzyme system etc.; Cellularity defending factors comprises macrophage, polymorphonuclear leukocyte and lymphocyte etc.If antibacterial enters after mammary gland, the virulence of antibacterial is strong, quantity is many or mammary gland defense mechanism is weak, then antibacterial can break through second defence line, settles down, breeds, cause disease in mammary gland; If bacterial virulence is low, quantity is few or mammary gland defense function is powerful, then antibacterial is eliminated, and can not produce mastopathy.
Mastitis is one of common disease of milch cow, and this disease is serious affects the seed output and quality of milk.When breast is inflamed, polymorphonuclear neutrophisls is assembled to inflammation part, causes the somatic cell quantity (somaticcellcount, SCC) in milk to raise.In inflammatory process, galactophore epithelial cell is destroyed, and the function reduction of the nutritional labelings such as mammary gland synthesis casein, butterfat and lactose, makes the nutritive value of breast reduce.If inflammation is smaller, can not perceive by naked eyes, this inflammation is called latent mammitis.If inflammation is serious, can perceive by naked eyes, claim clinic mastitis.The milch cow suffering from latent mammitis will greatly more than the milch cow of clinic mastitis, and latent mammitis easily develops into clinical type, causes larger harm.Latent mammitis does not have macroscopic clinical symptoms, is easily ignored by people, but it can cause the reduction of suffering from milk production and quality, and can give other milch cows by disease propagation by sick breast, causes the propagation of disease in cows.General discovery 1 clinic mastitis case, just may have the sick cattle of 15 ~ 40 latent mammitises in cows.Therefore, the medicine for the treatment of mastitis is provided to have realistic meaning.
At present, treatment mammitis of cow is mainly using antibiotic as major control means both at home and abroad, and especially clinic mastitis mainly adopts antibiotic therapy.Antibiotic therapy mainly directed toward bacteria itself works, or bacteria growing inhibiting or kill antibacterial, belongs to " taking stopgap measures ", energy symptom management within the short time the state of an illness itself.But owing to also cannot can not reach aseptic in milk cattle cultivating process, therefore use antibiotic therapy mammitis of cow just to need life-time service antibiotics.Mainly there is following shortcoming in life-time service antibiotics: one is that life-time service antibiotic can produce drug resistance to mammitis of cow pathogenic bacteria, causes the generation of superbacteria.Two is that antibiotic medication is frequent, once drug withdrawal, the state of an illness can increase the weight of.Three is the milk matter that life-time service antibiotic can affect cow producing milk, containing a large amount of antibiotic in milk, and harm humans food safety.But latent mammitis sickness rate is high, adopts antibiotic therapy can produce the discarded milk caused because of antibiotic remains in a large number to latent mammitis, cause larger economic loss to milk cow production.
Thymopentin (TP-5) is thymic neuroendocrine carcinoma (Thymopoietin II) 32nd ~ 36 amino acids residue segment, and all biological retaining thymic neuroendocrine carcinoma is active, is a kind of immunomodulator.Have induction and promote the function of T lymphocyte and subpopulations thereof, maturation and activation, the lymphocytic ratio of adjustment T, makes CD4+/CD8+ be tending towards normal; The effect of adjustment and reinforcement cellular immune function, T lymphocyte maturation in peripheral blood after mitogen can be impelled to activate, increase the secretion of T cell various lymphokine (as: α, IFN-γ, interleukin-22 and interleukin-13) after various antigen or the former activation of mitogenesis, increase the level of lymphokine receptor in T cell.It is simultaneously by strengthening lymphocyte reaction to the activation of t helper cell.In addition, Thymopentin may affect the chemotactic of NK precursor, and this precursor becomes after being exposed to interferon more has cytotoxicity.
Clinical trial proves, Thymopentin has good therapeutic effect at treatment malignant tumor, herpes simplex (HSV), diabetes and some autoimmune diseasees and severe immune deficiency syndrome.And TP-5 is one very safe drugs, is showed no toxicity in the acute, subacute of various animal and chronic toxicity test.Multiple common drug and Thymopentin use simultaneously, comprise various antibiotic, hormone, analgesic, anti-inflammatory agent, depressor, cardiac tonic, diuretic, beta-receptor antagonist, histamine receptor antagonist and medicine for central nervous system, all do not find that these medicines have interference effect to Thymopentin.But yet there are no the relevant report of the application of Thymopentin in preparation treatment mastitis especially mammitis of cow medicine.
Summary of the invention
In view of this, the invention provides the application of Thymopentin in preparation treatment mastitis medicine.Present invention also offers the application of Thymopentin in preparation treatment mammitis of cow medicine.The medicine that Thymopentin is prepared into is to the Be very effective of mammitis of cow.
In order to realize foregoing invention object, the invention provides following technical scheme:
The invention provides the application of Thymopentin in preparation treatment mastitis medicine.
Thymopentin is made up of arginine, lysine, aspartic acid, valine, tyrosine five seed amino acid, and its chemical name is N-(N-(N-(NL-arginyl-L-lysyl)-L-α-aspartoyl)-L-valyl)-TYR.Molecular formula is C
30h
49n
9o
9, molecular weight is 679.77.
The invention provides the application of Thymopentin in preparation treatment mammitis of cow medicine.The invention provides the application of Thymopentin in preparation treatment bovine subclinical mastitis and/or clinic mastitis medicine.
As preferably, the administering mode of the medicine that Thymopentin provided by the invention prepares is drug administration by injection.
As preferably, the administering mode of the medicine that Thymopentin provided by the invention prepares is lymphonodi mammarici targeting drug administration by injection.
As preferably, the dosage of the medicine that Thymopentin provided by the invention prepares is 2 ~ 20mg/ cow head.
The invention provides the application of Thymopentin in preparation treatment mastitis medicine.Present invention also offers the application of Thymopentin in preparation treatment mammitis of cow medicine.Latent mammitis test of pesticide effectiveness result shows, the infection breast district quantity of Thymopentin treatment group has the trend of minimizing after the treatment, especially be obviously with high dose group (4mg), and do not use in 10 Ge Ru districts in the blank group of Drug therapy, have the 9 each bacteriology checkings in Ge Ru district to be the positive.Thymopentin have activated mammary immune cell after injecting lymphonodi mammarici, and cytophagous engulfing is strengthened with sterilizing function, and the ability that mammary gland removes pathogen improves, and then infection breast district quantity is reduced.The clinic mastitis test of pesticide effectiveness shows, through for three days on end after lymphonodi mammarici injection Thymopentin (TP-5), the milk SCC of TP-5 bis-dosage groups (10mg, 20mg) all has downward trend, and the swelling of visual inspection cow breast is clearly better; Do not use the blank group of Drug therapy substantially constant at the SCC of duration of test, and mammary swelling have no improvement.Therefore the medicine that high dose Thymopentin (more than 10mg) is obtained is to the Be very effective of milch cow clinic mastitis.As can be seen here, the medicine that Thymopentin is obtained has remarkable result to latent mammitis and/or clinic mastitis.
Detailed description of the invention
The invention discloses the application of Thymopentin in preparation treatment mastitis medicine, those skilled in the art can use for reference present disclosure, and suitable improving technique parameter realizes.Special needs to be pointed out is, all similar replacements and change apparent to those skilled in the art, they are all deemed to be included in the present invention.Method of the present invention and application are described by preferred embodiment, related personnel obviously can not depart from content of the present invention, spirit and scope methods and applications as herein described are changed or suitably change with combination, realize and apply the technology of the present invention.
In the application of Thymopentin provided by the invention in preparation treatment mastitis medicine, agents useful for same, medicine all can be buied by market.
Below in conjunction with embodiment, set forth the present invention further:
Embodiment 1
Quick diagnosis bovine subclinical mastitis method (HMT): before spot sampling, discards three milk.The milk in tested cattle 4 Ge Ru district is squeezed 4 little indoor at diagnosis dish, and each cell is about 2ml, and each cell adds 2mlHMT diagnostic reagent.Shake diagnosis dish makes milk and reagent fully mix rear result of determination, and criterion is in table 1.
The criterion of table 1 bovine subclinical mastitis
Somatic Cell Count method: (1) corrects milk somatic cell counting instrument (FossomaticTMMinor, Denmark) with the standard substance that FOX company provides; (2), about testing milk sample (about 50ml) heating in water bath to 40 DEG C, mixing milk, detects with somatic cell counting instrument.
Case selection: Jin Jiang cattle farm, Suburban District of Hangzhou, Fresian 120, the mean age was 5.5 one full year of life.Detect each Niu Ru district milk sample with Hangzhou mastitis detectable (HMT), filter out the newborn district that HMT level of reaction is " ++ ~ +++ ".Bacteria distribution qualification is carried out to these Niu Ru district milk samples, and measures somatic number (SCC) with milk somatic cell counting instrument (FossomaticTMMinor, Denmark), filter out SCC 5 × 10
5individual/more than mL, and 49, the newborn district that Bacteria Identification is positive.Again gather milk sample same method after one week to analyze, check that milk SCC is all 5 × 10 for twice
5individual/more than mL, and 20, the newborn district that Bacteria Identification is still positive, totally 20 cow heads.
Thymopentin for injection (tp-5): the Thymopentin that Wal, Zhejiang becomes biological Pharmaceutical limited company to provide, often props up containing Thymopentin 2 milligrams, lot number 20110401.
Grouping and treatment: 20 test milch cows are divided into 4 groups at random: the basic, normal, high dosage group of trial drug, and blank group, often organize 5 cases.Three groups of cases of test group inject Thymopentin 1mg(low dose group respectively in the supramammary lymph node of ill Ru Qu side), 2mg(dosage group) and 4mg(high dose group), per injection medicine dissolution is in 1mL normal saline, once a day, treat 3 days continuously.Blank group, by the original method process in cattle farm, will not be treated.
Sampling: gather 2 milk samples before treatment, 1 week, interval; Within after treatment 1,2 week, gather milk sample, the preservation of low temperature fortune send laboratory to carry out bacteriology checking and Somatic Cell Count.
Statistical analysis: test data represents with geometric mean ± standard deviation, by the change of SCC of same group and the difference for the treatment of group and blank group before and after t check analysis process.Significance level is at P<0.05.The results are shown in Table 2.
The change unit of table 2 milk SCC: average (× 10
4)/mL ± SD
Note: * and * * represents and compare before treating have significant difference (P<0.05) and pole significant difference (P<0.01) respectively; A and A represents to compare between concurrent treatment group with blank group have significant difference (P<0.05) and pole significant difference (P<0.01) respectively.
Through for three days on end after lymphonodi mammarici injection Thymopentin (TP-5), TP-5 tri-dosage group (1mg, 2mg, milk SCC 4mg) all has downward trend, and wherein in TP-5, dosage group (2mg) and blank group compare and have significant difference (P<0.05); Do not use the blank group of Drug therapy substantially constant at the SCC of duration of test.
Become positive correlation according between bovine subclinical mastitis with somatic number (SCC), therefore, the medicine that Thymopentin obtains is to the Be very effective of bovine subclinical mastitis.
Embodiment 2
Other quick diagnosis bovine subclinical mastitis method (HMT) of cattle: with embodiment 1.
Somatic Cell Count method: with embodiment 1.
Bacteriology checking: carry out milk bacteriology checking according to NMC (NationalMastitisCouncil) recommended program.Concrete operation step is as follows: (1) first picking about 10 μ L milk sample is inoculated in Sheep Blood plating medium, 37 DEG C of constant temperature culture 24 ~ 48h.According to colony morphology characteristic, the suspicious bacterium colony smear of picking, Gram’s staining, microscopy; (2) 3 classes can be tentatively divided into according to bacteria growth, colonial morphology, dyeing characteristic, i.e. gram-positive cocci, Gram-positive bacillus, gram negative bacilli; (3) by catalase test, gram-positive cocci is divided into staphylococcus and streptococcus; (4) Streptococcus divides into streptococcus agalactiae, streptococcus dysgalactiae and streptococcus uberis etc. according to CAMP, Esculin, hippuric acid test.
Case selection: No. 5, Jin Jiang cattle farm, Suburban District of Hangzhou and No. 7 cowshed, Fresian 240.Detect each Niu Ru district milk sample by Hangzhou mastitis detectable (HMT, reagent can be buied by market), filter out 106, the newborn district that HMT level of reaction is " ++ ~ +++ ".Bacteria distribution qualification is carried out to these Niu Ru district milk samples, and measures somatic number (SCC) with milk somatic cell counting instrument (FossomaticTMMinor, Denmark), filter out SCC 5 × 10
5individual/more than mL, and the newborn district that Bacteria Identification is positive.Again gather milk sample same method after one week to analyze, check that milk SCC is all 5 × 10 for twice
5individual/more than mL, and 50, the newborn district that Bacteria Identification is still positive, totally 50 cow heads.
Medicine: thymopentin for injection (tp-5): Wal, Zhejiang becomes biological Pharmaceutical limited company pilot product, often props up containing Thymopentin 2 milligrams, lot number 201110401.Control drug: lincomycin, neomycin breast injection (trade name " mastitis ", containing lincomycin 330mg, neomycin 100mg), pioneer's animal pharmaceutical estate company limited of Chongqing City produces, and in October, 2010 date of manufacture, valid until in October, 2012.
Grouping and treatment: 50 test milch cows are divided into 5 groups at random: the basic, normal, high dosage group of trial drug and blank group, often organize 10 cases.Three groups of cases of test group inject Thymopentin 1mg(low dose group respectively in the supramammary lymph node of ill Ru Qu side), 2mg(dosage group) and 4mg(high dose group), by medicine dissolution in 1mL normal saline, once a day, treat 3 days continuously.The treatment by specification of positive drug control group carries out, and namely after milking, injects 10mL lincomycin, neomycin breast injection in the newborn district of each infection, treats twice continuously.Blank group, by the original method process in cattle farm, will not be treated.
Sampling: gather 2 milk samples before treatment, 1 week, interval; Within after treatment 1,2,3 week, gather 3 milk samples, cryopreservation send laboratory to carry out bacteriology checking and Somatic Cell Count.
Milk sample antibiotics leftover detection: after drug withdrawal 1 ~ 4 day, gathers milk sample every day 1 time, detects the antibiotic remains in milk with ECLIPSE50 test kit (Spain ZEU-INMUNOTEC Products).Get milk sample 50 μ L to add in the micropore of test kit plate, use diaphragm seal micropore, put observed result after 65 DEG C of water-bath 2 ~ 3h, in micropore, reagent color is green-yellow or yellowly represent negative, and indigo plant-purple represents positive.
Statistical analysis: test data represents with geometric mean ± standard deviation, by the change of SCC of same group and the difference for the treatment of group and blank group before and after t check analysis process.Significance level is at P<0.05.The results are shown in Table 3 to table 6.
Milk somatic cell number (SCC): compare with before treatment, milk SCC after thymopentin for injection (tp-5) (TP-5) and antibiotic (" mastitis ") treatment has obvious downward trend, wherein TP-5 high dose group (4mg) and antibiotic " mastitis " treatment group SCC fall are the most obvious, and blank group compared and had significant difference the same period.Slightly do not raise (see table 3) at duration of test with the blank group milk SCC of Drug therapy.
The change unit of table 3 milk SCC: average (× 10
4)/mL ± SD
Note: * and * * represents and compare before treating have significant difference (P<0.05) and pole significant difference (P<0.01) respectively; A and A represents to compare between concurrent treatment group with blank group have significant difference (P<0.05) and pole significant difference (P<0.01) respectively.
Infect the milk SCC in different bacterium breast district: from test cattle, find streptococcus agalactiae, staphylococcus aureus, streptococcus dysgalactiae, streptococcus uberis and coagulase negative staphylococcus.In milk SCC/mL with infected streptococcus agalactiae, staphylococcus aureus and streptococcus uberis newborn district higher, reach 800,000/more than mL, secondly for having infected the newborn district of streptococcus dysgalactiae and coagulase negative staphylococcus, in table 4.
Table 4 infects the milk SCC content in different bacterium breast district
| Antibacterial | Breast district number | SCC average (× 10 4）/mL±SD |
| Streptococcus agalactiae | 2 | 221.9±2.6 |
| Staphylococcus aureus | 15 | 91.4±50.4 |
| Streptococcus uberis | 7 | 86.7±34.0 |
| Streptococcus dysgalactiae | 16 | 71.9±27.6 |
| Coagulase negative staphylococcus | 12 | 71.8±33.6 |
Before and after treatment, milk bacteriology checking the results are shown in Table 5.Before treatment, the equal bacteriology checking in the newborn district of all tests is positive.After treatment, the quantity infecting newborn district reduces gradually.Check in 2 weeks after Drug therapy, the infection breast district quantity of each group is reduced to 4 ~ 6 from 10 Ge Ru districts before treatment.3rd weekly check, the infection breast district of TP-5 high dose group (4mg) only has 2, and the infection breast district of other treatment group is 4 ~ 5.The infection breast district of blank group remains high, and treating rear inspection for 3 times all has 9 to infect newborn district.
Local response after injection TP-5: be showed no the local untoward reaction such as pain, swelling at 30 cow heads of lymphonodi mammarici injection TP-5.
The newborn district number of the table 5 Bacteria Detection positive
* be milk sample bacteriology checking result before medication.
Antibiotics leftover detection result: table 6 result shows, the 1st, 2 day all newborn district after antibiotic therapy drug withdrawal, the 3rd day 6 Ge Ru districts, can detect antibiotic remains.Other is respectively organized and is not all detected that anti-element remains.
Table 6 duration of test respectively organizes in milk the newborn district number detecting antibiotic remains
Become positive correlation according between bovine subclinical mastitis with somatic number (SCC), therefore, the medicine that Thymopentin obtains is to the Be very effective of bovine subclinical mastitis.Above-mentioned result of the test shows, Thymopentin injects after lymphonodi mammarici, and infection breast district quantity is reduced, and shows that medicine that Thymopentin is prepared into is to the Be very effective of mammitis of cow.
High dose test also finds, the obtained medicine of high dose Thymopentin (4 ~ 20mg) is to the Be very effective of bovine subclinical mastitis.The Thymopentin effect that dosage is greater than 20mg is also extremely remarkable.
Embodiment 3
Clinic mastitis case selection: Jin Jiang cattle farm, Suburban District of Hangzhou, Fresian 120, the mean age was 5.5 one full year of life.Range estimation filters out breast redness, swelling, milch cow that milk yield is low, every Tou Niuru district milk sample is detected with Hangzhou mastitis detectable (HMT), filter out that HMT level of reaction is " +++ ", milk sample range estimation in canescence Zhuan Ru district, totally 15 cow heads, 15 Ge Ru districts.
Thymopentin for injection (tp-5): the Thymopentin that Wal, Zhejiang becomes biological Pharmaceutical limited company to provide, often props up containing Thymopentin 2 milligrams, lot number 20110401.
Grouping and treatment: 15 test milch cows are divided into 3 groups at random: the middle and high dosage group of trial drug, and blank group, often organize 5 cases.Three groups of cases of test group inject Thymopentin 10mg(dosage group respectively in the supramammary lymph node of ill Ru Qu side) and 20mg(high dose group), per injection medicine dissolution, in 5mL normal saline, once a day, is treated 3 days continuously.Blank group, by the original method process in cattle farm, will not be treated.
Sampling: gather 1 milk sample before treatment; Milk sample was gathered in the 3rd, 7 day, Site Detection HMT level of reaction after treatment.
The results are shown in Table 7.
Table 7 mammitis of cow clinical symptoms change
Through for three days on end after lymphonodi mammarici injection Thymopentin (TP-5), the milk SCC of TP-5 bis-dosage groups (10mg, 20mg) all has downward trend, and the swelling of visual inspection cow breast is clearly better; Do not use the blank group of Drug therapy substantially constant at the SCC of duration of test, and mammary swelling have no improvement.
High dose test also finds, the medicine that high dose Thymopentin (more than 10mg) obtains is to the Be very effective of milch cow clinic mastitis.
The above is only the preferred embodiment of the present invention; it should be pointed out that for those skilled in the art, under the premise without departing from the principles of the invention; can also make some improvements and modifications, these improvements and modifications also should be considered as protection scope of the present invention.
Claims (2)
1. the application of Thymopentin separately in preparation treatment mammitis of cow injectable drug.
2. the application of Thymopentin separately in preparation treatment bovine subclinical mastitis and/or clinic mastitis injectable drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210146059.2A CN103386115B (en) | 2012-05-11 | 2012-05-11 | The application of Thymopentin in preparation treatment mastitis medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210146059.2A CN103386115B (en) | 2012-05-11 | 2012-05-11 | The application of Thymopentin in preparation treatment mastitis medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103386115A CN103386115A (en) | 2013-11-13 |
| CN103386115B true CN103386115B (en) | 2015-11-25 |
Family
ID=49530649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210146059.2A Active CN103386115B (en) | 2012-05-11 | 2012-05-11 | The application of Thymopentin in preparation treatment mastitis medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103386115B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106117315B (en) * | 2016-07-19 | 2019-07-30 | 吉林大学 | Medical application of the pentapeptide in treatment S. aureus L-forms mastitis for milk cows |
| CN106188233B (en) * | 2016-07-19 | 2019-07-05 | 吉林大学 | A kind of polypeptide that treating S. aureus L-forms mastitis for milk cows and preparation process |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101244255A (en) * | 2007-02-14 | 2008-08-20 | 成都地奥九泓制药厂 | Thymus gland pentapeptide injection and uses thereof |
| WO2009033749A2 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of thymopentin as a therapeutic agent |
| CN103239709A (en) * | 2013-04-25 | 2013-08-14 | 浙江大学 | Preparation method and use of thymopentin sustained-release preparation |
-
2012
- 2012-05-11 CN CN201210146059.2A patent/CN103386115B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101244255A (en) * | 2007-02-14 | 2008-08-20 | 成都地奥九泓制药厂 | Thymus gland pentapeptide injection and uses thereof |
| WO2009033749A2 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of thymopentin as a therapeutic agent |
| CN103239709A (en) * | 2013-04-25 | 2013-08-14 | 浙江大学 | Preparation method and use of thymopentin sustained-release preparation |
Non-Patent Citations (2)
| Title |
|---|
| ******内注射胸腺五肽治疗奶牛隐形***炎的研究;潘韬等;《中国兽医学报》;20130930;第33卷(第9期);1341-1345 * |
| 兽药精品治疗猪胃肠炎濮阳;河南正源动物药业有限公司;《www.ggsgg.com/10/69904/698626.shtml》;20100811;全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103386115A (en) | 2013-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| McDougall | Efficacy of two antibiotic treatments in curing clinical and subclinical mastitis in lactating dairy cows | |
| Cao et al. | Efficacy of nisin in treatment of clinical mastitis in lactating dairy cows | |
| Enginler et al. | Comparison of intramammary ozone administration doses in dairy cows with clinical mastitis | |
| CN103386115B (en) | The application of Thymopentin in preparation treatment mastitis medicine | |
| CN103989729A (en) | Acalypha australis L. and sulfamonomethoxine sodium containing compound medicine for livestock and poultry | |
| CN113082060B (en) | Preparation and application of phage cocktail preparation for treating dairy cow mastitis | |
| CN103989726A (en) | Acalypha australis L. and fosfomycin containing compound medicine for livestock and poultry | |
| Bolourchi et al. | Comparison of the effects of local and systemic dry cow therapy for staphylococcal mastitis control | |
| Tyler et al. | Treatment of subclinical mastitis | |
| CN113908121B (en) | Niclosamide injection and preparation and application thereof | |
| CN105079000B (en) | A kind of composition and its application, preparation | |
| Ospina et al. | Randomized noninferiority field trial comparing 2 first-generation cephalosporin products at dry off in quarters receiving an internal teat sealant in dairy cows | |
| RU2385729C1 (en) | Method for prevention of respiratory disease and improving fertility in young deers | |
| CN101247721B (en) | Pharmaceutical composition and using method thereof including casein derived peptides | |
| CN111544582A (en) | Swine dysentery nebulized vaccine and preparation method thereof | |
| CN104622803A (en) | Breast injectant for treating mastitis of lactating dairy cows and preparation method of breast injectant | |
| Shkromada et al. | Treatment of subclinical mastitis of cows with probiotics | |
| CN103239709B (en) | Preparation method and use of thymopentin sustained-release preparation | |
| CN104523863B (en) | A kind of traditional Chinese medicine infusion solution and its preparation method and application | |
| Guan et al. | Subcutaneous injection of thymopentin in the area of the supramammary lymph node to reduce milk somatic cell count in subclinically mastitic cows | |
| RU2687041C1 (en) | Biopreparation for cows endometritis prevention and treatment | |
| Ortega et al. | A non-inferiority study evaluating a new extended-release preparation of tilmicosin injected subcutaneously vs. ceftiofur administered intramammary, as dry-cow therapy in Holstein Friesian cows | |
| Vakanjac et al. | Testing the efficiency of different treatments of subclinical Staphylococcus aureus mastitis in cows during the dry period | |
| RU2274462C1 (en) | Method for treating and preventing piglet nematodosis | |
| Kumar et al. | Studies on therapeutic efficacy of poly herbal formulation in management of sub clinical mastitis in dairy cattle |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |